Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Nektar Therapeutics's current 1-Year Share Buyback Ratio was -174.00%.
FRA:ITH0's 1-Year Share Buyback Ratio is ranked worse than 90.51% of 1107
companies
in the Biotechnology industry
Industry Median: -14.6
vs FRA:ITH0: -174.00
Nektar Therapeutics (FRA:ITH0) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Nektar Therapeutics 1-Year Share Buyback Ratio Related Terms
FRA:ITH0 vs PHVS, PGEN, VERA: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Nektar Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -174.00 mean?
Nektar Therapeutics (FRA:ITH0) has a 1-Year Share Buyback Ratio of -174.00 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Nektar Therapeutics and its competitors. According to the industry distribution chart, Nektar Therapeutics ranks #1002 out of 1107 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Nektar Therapeutics' 1-Year Share Buyback Ratio too high?
Nektar Therapeutics' current 1-Year Share Buyback Ratio is -174.00. Based on the distribution chart, Nektar Therapeutics ranks #1002 out of 1107 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nektar Therapeutics has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' 1-Year Share Buyback Ratio compare to PHVS and PGEN?
According to the Biotechnology industry distribution chart, Nektar Therapeutics ranks #1002 out of 1107 companies for 1-Year Share Buyback Ratio. This places Nektar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Nektar Therapeutics and its competitors. Nektar Therapeutics's current 1-Year Share Buyback Ratio is -174.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.68, compared to a current price of €60.46 — trading 1191.9% above its estimated fair value. The current 1-Year Share Buyback Ratio is -174.00. Nektar Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current 1-Year Share Buyback Ratio is -174.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?
Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued.
The current stock price of €60.46 is trading 1191.9% above its estimated GF Value™ of €4.68.
GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:ITH0:
1-Year Share Buyback Ratio: -174.00
GF Value™: €4.68 vs. price of €60.46 (1191.9% above fair value)
No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
50GF Score
Get the complete analysis for FRA:ITH0
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ITH0 has been successfully added to your 
